Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...
Untreated mental health issues, like Treatment-Resistant Depression (TRD), cost U.S. businesses billions annually in lost ...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...
Highlights: Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025 Phase 3 COMP006 in TRD is on track for ...
We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...
For Coral Springs residents who have struggled with depression and found little success with conventional treatments, Neuro ...